Former CMO and Execute VP of ASCO on Molecular Profiling in GI Cancer and Health Inequity

Video

Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.

Richard Schilsky, MD, former Chief Medical Officer (CMO) and Executive Vice President of ASCO, spoke with CancerNetwork® about molecular profiling driving progress in gastrointestinal cancers, which was named ASCO’s Advance of the Year in “Clinical Cancer Advances 2021.”

Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving forward, and more.

He also explained the changes forced on clinical trials due to the coronavirus disease 2019 (COVID-19) pandemic, and how he anticipates trials can leverage these adjustments moving forward in a post-COVID world.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content
PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

Ariana Pelosci
October 22nd 2024
Article

The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Adrienne Bruce Shannon, MD;Sean Dineen, MD;Muhammad Talha Waheed, MD
April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers

Russ Conroy
September 26th 2024
Article

Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates

Jun Gong, MD;Daneng Li, MD
February 19th 2024
Podcast

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.

Omission of 5-FU From Combo Therapy May Improve Results in Advanced GI Cancers

Harrison Widelitz
September 9th 2024
Article

The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.

Expert Commentary on the Product Profile of Tislelizumab in Advanced Esophageal Cancer

Expert Commentary on the Product Profile of Tislelizumab in Advanced Esophageal Cancer

Krystal Preston, PharmD, BCPS
August 21st 2024
Article

Krystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.